Fundraising FoxLeap Therapeutics
Cambridge, US · Delaware corporation · 2 known investors
Find your way into Leap Therapeutics
Sign up to see every warm intro you have to Leap Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Leap Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oncology company developing targeted and immuno-oncology therapeutics; lead candidate DKN-01 targets the DKK1 protein.
Founders & leadership
AL
Augustine LawlorChief Operating Officer
DO
Douglas OnsiChief Financial Officer
TD
Thomas DietzNamed on SEC filing
JL
Joseph LoscalzoNamed on SEC filing
NM
Nissim MashiachNamed on SEC filing
WL
William LiNamed on SEC filing
Board
JL
John LittlechildBoard director
JC
James CavanaughBoard director
Investors · 2
Funding
SEC filings, press & company announcements$95.2M disclosed across 2 of 5 rounds · 2017–2025
- Undisclosed amountPIPEOct 2025Source ↗
- Undisclosed amountPrivate PlacementOct 2025
Winklevoss Capital (lead)
Source ↗
▶$77.2MraisedMar 2023 · 121 investors · PharmaceuticalsRule 506(b)
▶$77.2MraisedMar 2023 · 121 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph LoscalzoDirector
- Christian RichardDirector
- Christine GranfieldExecutive Officer
- Patricia MartinDirector
- Nissim MashiachDirector
- Christopher K. MirabelliDirector
- Cynthia SirardExecutive Officer
- James CavanaughDirector
- Richard SchilskyDirector
- Augustine LawlorExecutive Officer
- William LiDirector
- Thomas DietzDirector
- Mark O'MahonyExecutive Officer
- Douglas E. OnsiExecutive Officer, Director
- Offering amount
- $77.2M
- Amount sold
- $77.2M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedNov 2017 · 14 investors · BiotechnologyRule 506(b)
▶$18MraisedNov 2017 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John LittlechildDirector
- Thomas DietzDirector
- Joseph LoscalzoDirector
- Nissim MashiachDirector
- James CavanaughDirector
- Douglas OnsiExecutive Officer
- Christopher MirabelliExecutive Officer, Director
- William LiDirector
- Augustine LawlorExecutive Officer
- Offering amount
- $18M
- Amount sold
- $18M
- Sales commissions
- $400K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Leap Therapeutics do?
- Oncology company developing targeted and immuno-oncology therapeutics; lead candidate DKN-01 targets the DKK1 protein.
- Who founded Leap Therapeutics?
- Leap Therapeutics was founded by Christopher Mirabelli, Augustine Lawlor.
- Who are Leap Therapeutics's investors?
- Leap Therapeutics's investors include Torrey Pines Investment, Winklevoss Capital.
- How much funding has Leap Therapeutics raised?
- Leap Therapeutics has disclosed $95.2M raised across 2 of its 5 known rounds.
- Where is Leap Therapeutics headquartered?
- Leap Therapeutics is headquartered in Cambridge, US.